Portage Biotech (NASDAQ:ATON) Shares Up 3.8% – Here’s What Happened

Portage Biotech Inc. (NASDAQ:ATON)’s stock price traded up 3.8% during mid-day trading on Thursday . The stock traded as high as $0.3504 and last traded at $0.3320. 9,777,470 shares were traded during trading, an increase of 209% from the average daily volume of 3,165,393 shares. The stock had previously closed at $0.32.

Analyst Ratings Changes

Separately, HC Wainwright started coverage on shares of Portage Biotech in a research report on Tuesday, February 24th. They issued a “buy” rating and a $2.00 price objective on the stock. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Portage Biotech presently has an average rating of “Hold” and an average target price of $2.00.

Portage Biotech Stock Performance

The stock’s 50 day moving average is $0.33. The company has a market capitalization of $7.78 million, a PE ratio of -0.04 and a beta of 0.49.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.